Sanofi signs stem cell pact in China
Sanofi-aventis announced that it has signed a deal to collaborate with the Chinese Academy of Medical Sciences on stem cell research. Sanofi hopes to isolate acute myeloid leukemia stem cells and generate of monoclonal antibodies against these cells. New therapeutics could be built from the research.
During a signing ceremony held in Beijing, China, Dr. Qi-Min Zhan, Vice President Research, Chinese Academy of Medical Sciences touted the pact. "This collaboration with a large and well-known pharmaceutical company is a significant progress for the academy; it clearly demonstrates that the work of our scientists on the leading-edge of cancer research is acknowledged. We actively encourage many more such initiatives."
China is becoming an increasingly attractive R&D site for major pharmaceutical companies. While it has already made tremendous inroads as a manufacturing center for the world, it's now making enormous investments in R&D to propel the country into the top ranks of world innovators.
- see Sanofi's release
Related Articles:
China now leads India in ongoing clinical trials. Report
China's pharma market steams ahead. Report
China pushes drug development as R&D soars. Report
Comments (1) | Post a comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets